Ocular Therapeutix Stock News

Small-cap stocks often rise in response to interest rate cuts. Archer Aviation and Ocular Therapeutix may be ideal candidates to buy ahead of this potential catalyst.

The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise

Ocular Therapeutix (OCUL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in

Three under-$15 stocks stand out in the stock market for their massive potential and strategic positioning across diverse sectors. They have all carved unique paths towards growth.

BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people's vision and quali

The consensus price target hints at a 34.7% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share a year ago.

BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, the “Company”), a biopharmaceutical company committed to enhancing people's vision and quality of life th

Ocular Therapeutix (OCUL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Does Ocular Therapeutix (OCUL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Ocular Therapeutix (OCUL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

While people tend to avoid price hikes, certain stocks up 100% this year just might provide an exception to the rule. Basically, not even two months have passed by.

The average of price targets set by Wall Street analysts indicates a potential upside of 64.6% in Ocular Therapeutix (OCUL). While the effectiveness of this highly sought-after metric is questionable,

Ocular Therapeutix and Fat Brands have solid growth and momentum in SA Quant Factor Grades with potentially high upside in line with consensus price targets. Ocular Therapeutix is up over 50% in the p

Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i